KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword [PDF]
, 2017 The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a selective update of the ...
Wheeler, DC, Winkelmayer, WC
core
PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
PLoS ONE, 2017 The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated.
Atsushi Yaguchi +3 more
doaj +1 more source
PILOTSTUDY TO EVALUATE THE EFFECT OF PHOSPHORUSBINDERS ON FGF23
Kidney Research and Clinical Practice, 2012 The Netherlands Fibroblast growth Factor 23 (FGF23) is independently associated with cardiovasculair outcome. A reduction of dietary phosphorus intake in healthy individuals leads to a decrease of FGF23.
A.Bouma de Krijger +3 more
doaj +1 more source
The connections between vascular calcification and bone health [PDF]
, 2013 Vascular calcification, bone loss and increased fracture risk are age-associated disorders. Several epidemiological studies have suggested a relationship between vascular calcification, impaired bone metabolism and increased mortality.
Cannata, J.B. (Jorge) +2 more
core
Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE−/−) mice with chronic renal failure [PDF]
, 2017 Background. In chronic kidney disease (CKD) patients, the intake of calcium-based phosphate binders is associated with a marked progression of coronary artery and aortic calcification, in contrast to patients receiving calcium-free phosphate binders. The
Chasseraud, Maud +10 more
core
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients
International Journal of Nephrology and Renovascular Disease, 2014 Shahrzad OssarehDepartment of Medicine, Nephrology Section, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, IranAbstract: Phosphate control is still a great challenge in chronic kidney disease (CKD), and in spite of the great ...
Ossareh S
doaj
Assessing the real-world drug safety of sevelamer for hyperphosphatemia: Insights from a comprehensive analysis of the FDA adverse event reporting system (FAERS) database. [PDF]
Medicine (Baltimore)Shao X, Yang H, Tan C, Liu J, Zhou L.
europepmc +1 more source
Risk factors for drug-related gastrointestinal ulcer:a retrospective pharmacovigilance study. [PDF]
Front PharmacolJiang S +8 more
europepmc +1 more source
Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease. [PDF]
World J NephrolIlkun O, Jazayeri F, Kazory A.
europepmc +1 more source
Evanescent extraosseous calcifications in low turnover bone: management and outcomes: a case report. [PDF]
Front NephrolHernandez-Pérez M, Enos D.
europepmc +1 more source